.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,011,846

« Back to Dashboard

Details for Patent: 5,011,846

Title: Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
Abstract:The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for the treatment of anxiety, psychosis, glaucoma and for the stimulation of gastric motility.
Inventor(s): Gittos; Maurice W. (Plobsheim, FR), Miller; Francis P. (Loveland, OH), Sorensen; Stephen M. (Cincinnati, OH), Fozard; John R. (Hegenheim, FR), Moser; Paul (Strasbourg, FR), Palfreyman; Michael G. (Cincinnati, OH), Cheng; Hsien (Cincinnati, OH)
Assignee: Merrell Dow Pharmaceuticals Inc. (Cincinnati, OH)
Filing Date:May 16, 1990
Application Number:07/527,676
Claims:1. A pharmaceutical composition suitable for use in the treatment of anxiety, psychosis, glaucoma, and for stimulating gastric motility comprising a pharmaceutically acceptable carrier in admixture with a compound of the formula ##STR7## wherein A is H.sub.2, O, (H)(OH), (OH).sub.2 or N--OH; B is H.sub.2, (H)(CH.sub.3), (H)(CH.sub.2 NR.sub.3 R.sub.4) or CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 ; R.sub.1 is ##STR8## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, alkoxy, or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl (C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxyl, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl; the wavy line indicates that the configuration of the oxygen substituent on the ring can be endo or exo; and the pharmaceutically acceptable acid addition and quarternary ammonium salts of the aforesaid compounds.

2. A pharmaceutical composition according to claim 1 wherein said compound is endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-on e.

3. A method for the treatment of anxiety comprising administering to a patient in need thereof of an effective amount of a compound of the formula ##STR9## wherein A is H.sub.2, O, (H)(OH), (OH).sub.2 or N--OH; B is H.sub.2, (H)(CH.sub.3), (H)(CH.sub.2 NR.sub.3 R.sub.4) or CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --; R.sub.1 is ##STR10## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl (C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl; the wavy line indicates that the configuration of the oxygen substituent on the ring can be endo or exo; and the pharmaceutically acceptable acid addition and quarternary ammonium salts of the aforesaid compounds.

4. A method according to claim 3 wherein said compound is endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-on e.

5. A method for the treatment of psychosis comprising administering to a patient in need thereof an effective amount of a compound of the formula ##STR11## wherein A is H.sub.2, O, (H)(OH), (OH).sub.2 or N--OH; B is H.sub.2, (H)(CH.sub.3), (H)(CH.sub.2 NR.sub.3 R.sub.4) or CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --; R.sub.1 is ##STR12## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl (C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl; the wavy line indicates that the configuration of the oxygen substituent on the ring can be endo or exo; and the pharmaceutically acceptable acid addition and quarternary ammonium salts of the aforesaid compounds.

6. A method according to claim 5 wherein said compound is endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-on e.

7. A method for stimulating gastric motility comprising administering to a patient in need thereof an effective amount of a compound of the formula: ##STR13## wherein A is H.sub.2, O, (H)(OH), (OH).sub.2 or N--OH; B is H.sub.2, (H)(CH.sub.3), (H)(CH.sub.2 NH.sub.3 R.sub.4) or CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --; R.sub.1 is ##STR14## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl (C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1-4 alkyl or phenyl; the wavy line indicates that the configuration of the oxygen substituent on the ring can be endo or exo; and the pharmaceutically acceptable acid addition and quarternary ammonium salts of the aforesaid compounds.

8. A method according to claim 7 wherein said compound is endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-on e.

9. A method for the treatment of glaucoma comprising administering to a patient in need thereof an effective amount of a compound of the formula: ##STR15## wherein A is H.sub.2, O, (H)(OH), (OH).sub.2 or N--OH; B is H.sub.2, (H)(CH.sub.3), (H)(CH.sub.2 NR.sub.3 R.sub.4) or CH.sub.2 wherein R.sub.3 and R.sub.4 are C.sub.2-4 alkyl or are combined to give tetramethylene, pentamethylene or --CH.sub.2 CH.sub.2 --O--CH.sub.2 CH.sub.2 --; R.sub.1 is ##STR16## wherein Z is NR.sub.9, O or S; R.sub.5, R.sub.6 and R.sub.8 are each hydrogen, halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy; R.sub.7 is hydrogen, amino, (C.sub.1-4 alkyl)amino, (C.sub.1-4 alkyl).sub.2 amino, alkoxy or nitro; R.sub.9 is hydrogen, C.sub.1-4 alkyl or phenyl (C.sub.1-2 alkyl); R.sub.10 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, cyano or --CONH.sub.2 ; R.sub.11 is hydrogen, halogen, C.sub.1.varies.4 alkyl or phenyl; the wavy line indicates that the configuration of the oxygen substituent on the ring can be endo or exo; and the pharmaceutically acceptable acid addition and quarternary ammonium salts of the aforesaid compounds.

10. A method according to claim 9 wherein said compound is endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-on e.

11. A pharmaceutical composition according to claim 1 wherein said compound is endo-8-(3-indolylcarbonyl-oxy)-2,6-methanooctahydro-2H-quinolizin-3-ol.

12. A method according to claim 3 wherein said compound is endo-8-(3-indolylcarbonyl-oxy)-2,6-methanooctahydro-2H-quinolizin-3-ol.

13. A method according to claim 5 wherein said compound is endo-8-(3-indolylcarbonyl-oxy)-2,6-methanooctahydro-2H-quinolizin-3-ol.

14. A method according to claim 7 wherein said compound is endo-8-(3-indolylcarbonyl-oxy)-2,6-methanooctahydro-2H-quinolizin-3-ol.

15. A method according to claim 9 wherein said compound is endo-8-(3-indolylcarbonyl-oxy)-2,6-methanooctahydro-2H-quinolizin-3-ol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc